Moderna and Merck report melanoma vaccine cut recurrence risk in trial
Moderna and Merck said a personalized mRNA cancer vaccine cut the risk of melanoma recurrence by 42% compared with standard treatment in a large clinical trial. The trial results also suggested patients went longer without their cancer returning. STAT…
